Supported by ongoing funding from the European Innovation Council (EIC) Accelerator, the partnership aims to optimize and scale production for future clinical trials.

”Partnering with NorthX Biologics is an important step in preparing our therapy for future trials beyond the current Phase 1 study. Establishing a reliable and cost-effective manufacturing process is key to our clinical and commercial goals. We’re excited for our team to work closely with NorthX’s experts, combining our strengths to develop a scalable solution that will allow us to treat a larger patient population as we advance,”

says Samuel Svensson, CEO of NEOGAP Therapeutics.

Personalised Tumour Trained Lymphocytes

NEOGAP Therapeutics develops pTTL (personalised Tumour Trained Lymphocytes), a cell therapy designed to treat solid tumors by training the immune system to recognize and attack cancer cells through the patient’s unique neoantigens. Currently, pTTL is under evaluation in a Phase I/II clinical trial focused on assessing its safety and tolerability in patients with advanced colorectal cancer.

The collaboration, carried out within the framework of the EIC Accelerator program, aims to establish a robust, cost-effective production setup that enhances both productivity and scalability. The project includes a comprehensive analysis of NEOGAP’s manufacturing protocols, with a focus on scale-out strategies and GMP process industrialisation to support large-scale clinical trials and eventual commercialisation. The goal is to implement streamlined production processes and logistics, increasing resilience and cost-effectiveness as NEOGAP progresses toward broader clinical applications and greater patient access.